Advertisement
U.S. markets close in 4 hours 51 minutes

Ionis Pharmaceuticals, Inc. (IONS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
43.47-0.88 (-1.99%)
As of 11:09AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close44.35
Open44.40
Bid43.75 x 900
Ask43.82 x 1100
Day's Range43.36 - 46.23
52 Week Range32.69 - 54.44
Volume518,887
Avg. Volume1,176,221
Market Cap6.236B
Beta (5Y Monthly)0.46
PE Ratio (TTM)N/A
EPS (TTM)-2.87
Earnings DateFeb 21, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est55.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IONS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Ionis Pharmaceuticals, Inc.
    Analyst Report: Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
    Rating
    Fair Value
    Economic Moat
    4 months agoMorningstar
View more